Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof.

Abstract: Chemical compositions are disclosed. One exemplary composition, among others, includes: a basic component, an acidic component, at least one acrylate component, oxidizing agent, reducing agent, and a binder. The binder includes a viscosity modifier and a surface tension modifier. The binder is capable of stimulating a reaction between the basic component and the acidic component. A portion of the binder is capable of undergoing a polymerization reaction between at least one acrylate component, the oxidizing agent, and the reducing agent. The polymerization reaction being initiated by the redox reaction between the oxidizing agent and the reducing agent.

Abstract: Compositions, methods of using the compositions, and solid freeform fabrication (SFF) systems for producing three-dimensional objects are disclosed. One exemplary composition, among others, includes a basic component, an acidic component, at least one monoacrylate component, a light sensitive initiator, and a polar binder. A polymerization reaction between the at least one monoacrylate component and the light sensitive initiator occurs upon exposure to optical energy. The polar binder includes a viscosity modifier and a surface tension modifier. The polar binder is capable of stimulating a crosslinking reaction between the basic component and the acidic component.

Abstract: he present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure, comprising administering to a patient in need thereof an effective amount of a compound of the formula: I or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.